Ivan Peyron

559 total citations
36 papers, 397 citations indexed

About

Ivan Peyron is a scholar working on Hematology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Ivan Peyron has authored 36 papers receiving a total of 397 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Hematology, 11 papers in Immunology and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Ivan Peyron's work include Platelet Disorders and Treatments (21 papers), Hemophilia Treatment and Research (15 papers) and Complement system in diseases (10 papers). Ivan Peyron is often cited by papers focused on Platelet Disorders and Treatments (21 papers), Hemophilia Treatment and Research (15 papers) and Complement system in diseases (10 papers). Ivan Peyron collaborates with scholars based in France, Netherlands and United States. Ivan Peyron's co-authors include Srini V. Kaveri, Sébastien Lacroix‐Desmazes, Jan Voorberg, Sandrine Delignat, Anja ten Brinke, Peter J. Lenting, Jordan D. Dimitrov, Cécile V. Denis, Olivier D. Christophe and Caterina Casari and has published in prestigious journals such as Blood, The Journal of Immunology and PLoS ONE.

In The Last Decade

Ivan Peyron

35 papers receiving 387 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ivan Peyron France 14 266 103 91 90 54 36 397
Julie Pegon France 6 236 0.9× 132 1.3× 23 0.3× 79 0.9× 54 1.0× 7 357
Matthew W. Anderson United States 7 66 0.2× 168 1.6× 24 0.3× 72 0.8× 33 0.6× 12 281
Y Hamano Japan 5 50 0.2× 206 2.0× 109 1.2× 74 0.8× 46 0.9× 8 319
Anne Schoolmeester Belgium 5 218 0.8× 73 0.7× 53 0.6× 56 0.6× 29 0.5× 5 325
Kristell Lebozec France 7 144 0.5× 27 0.3× 32 0.4× 109 1.2× 10 0.2× 7 321
PI Terasaki United States 7 80 0.3× 105 1.0× 41 0.5× 37 0.4× 37 0.7× 12 250
Cornelis E. Hack Netherlands 7 61 0.2× 148 1.4× 17 0.2× 52 0.6× 96 1.8× 8 295
Louis Deforche Belgium 6 184 0.7× 252 2.4× 21 0.2× 30 0.3× 132 2.4× 6 311
Ria C. Boertjes Netherlands 6 246 0.9× 72 0.7× 9 0.1× 35 0.4× 74 1.4× 6 355
Karen Hambardzumyan Sweden 9 58 0.2× 63 0.6× 34 0.4× 29 0.3× 43 0.8× 15 282

Countries citing papers authored by Ivan Peyron

Since Specialization
Citations

This map shows the geographic impact of Ivan Peyron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ivan Peyron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ivan Peyron more than expected).

Fields of papers citing papers by Ivan Peyron

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ivan Peyron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ivan Peyron. The network helps show where Ivan Peyron may publish in the future.

Co-authorship network of co-authors of Ivan Peyron

This figure shows the co-authorship network connecting the top 25 collaborators of Ivan Peyron. A scholar is included among the top collaborators of Ivan Peyron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ivan Peyron. Ivan Peyron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Clavel, Marie‐Annick, Ivan Peyron, Tovo David, et al.. (2025). <i>Erratum</i> to: “Consistent clinical factor VIII equivalency is unlikely for non-factor therapies in hemophilic mice”. Haematologica. 110(12). 3182–3183.
2.
Clavel, Marie‐Annick, Ivan Peyron, Tovo David, et al.. (2025). Consistent clinical factor VIII equivalency is unlikely for non-factor therapies in hemophilic mice. Haematologica. 110(9). 2064–2075. 2 indexed citations
3.
Peyron, Ivan, Caterina Casari, Stéphanie Roullet, et al.. (2025). A bispecific nanobody for the treatment of von Willebrand disease type 1. Blood. 146(21). 2597–2607. 1 indexed citations
4.
Heestermans, Marco, Ivan Peyron, Marie‐Annick Clavel, et al.. (2024). A fully humanized von Willebrand disease type 1 mouse model as unique platform to investigate novel therapeutic options. Haematologica. 110(4). 923–937. 4 indexed citations
5.
Delignat, Sandrine, Maxime Lecerf, Rémi Noé, et al.. (2023). Transplacental delivery of therapeutic proteins by engineered immunoglobulin G: a step toward perinatal replacement therapy. Journal of Thrombosis and Haemostasis. 21(9). 2405–2417. 5 indexed citations
6.
Peyron, Ivan, Caterina Casari, Olivier D. Christophe, Peter J. Lenting, & Cécile V. Denis. (2023). KB-V13A12, a novel nanobody-based therapeutic molecule for the treatment of von Willebrand disease. SPIRE - Sciences Po Institutional REpository. 2 indexed citations
7.
Delignat, Sandrine, Ivan Peyron, Claire Deligne, et al.. (2023). Imlifidase, a new option to optimize the management of patients with hemophilia A on emicizumab. Journal of Thrombosis and Haemostasis. 21(10). 2776–2783. 4 indexed citations
8.
Peyron, Ivan, Caterina Casari, Olivier D. Christophe, Peter J. Lenting, & Cécile V. Denis. (2023). OC 08.3 KB-V13A12, a Novel Nanobody-based Therapeutic Molecule for the Treatment of Von Willebrand Disease. Research and Practice in Thrombosis and Haemostasis. 7. 100545–100545. 7 indexed citations
9.
Adam, Frédéric, Elsa P. Bianchini, Ivan Peyron, et al.. (2022). Antithrombotic potential of a single‐domain antibody enhancing the activated protein C‐cofactor activity of protein S. Journal of Thrombosis and Haemostasis. 20(7). 1653–1664. 2 indexed citations
10.
Peyron, Ivan, Serge Pierre‐Louis, Pierre Boisseau, et al.. (2022). Identification of von Willebrand factor D4 domain mutations in patients of Afro‐Caribbean descent: In vitro characterization. Research and Practice in Thrombosis and Haemostasis. 6(4). e12737–e12737. 2 indexed citations
11.
Peyron, Ivan, et al.. (2020). Camelid‐derived single‐chain antibodies in hemostasis: Mechanistic, diagnostic, and therapeutic applications. Research and Practice in Thrombosis and Haemostasis. 4(7). 1087–1100. 10 indexed citations
12.
Peyron, Ivan, Olivier D. Christophe, Charlotte Kawecki, et al.. (2020). A hemophilia A mouse model for the in vivo assessment of emicizumab function. Blood. 136(6). 740–748. 44 indexed citations
13.
Delignat, Sandrine, Ivan Peyron, Maxime Lecerf, et al.. (2020). Relevance of the Materno-Fetal Interface for the Induction of Antigen-Specific Immune Tolerance. Frontiers in Immunology. 11. 810–810. 12 indexed citations
14.
15.
Saris, Anno, Pieter F. van der Meer, Ivan Peyron, et al.. (2017). The Role of Platelets in the Induction of Alloimmunization after Platelet Transfusion. Blood. 130. 3726–3726. 2 indexed citations
16.
Gilardin, Laurent, Sandrine Delignat, Ivan Peyron, et al.. (2017). The ADAMTS13 1239–1253 peptide is a dominant HLA-DR1-restricted CD4 + T-cell epitope. Haematologica. 102(11). 1833–1841. 10 indexed citations
17.
Mahendra, Ankit, Ivan Peyron, Olivier Thaunat, et al.. (2016). Generation of Catalytic Antibodies Is an Intrinsic Property of an Individual’s Immune System: A Study on a Large Cohort of Renal Transplant Patients. The Journal of Immunology. 196(10). 4075–4081. 3 indexed citations
18.
Gangadharan, Bagirath, et al.. (2016). The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells. Haematologica. 102(2). 271–281. 31 indexed citations
19.
Repessé, Yohann, Jordan D. Dimitrov, Ivan Peyron, et al.. (2012). Heme binds to factor VIII and inhibits its interaction with activated factor IX. Journal of Thrombosis and Haemostasis. 10(6). 1062–1071. 22 indexed citations
20.
Mahendra, Ankit, Meenu Sharma, Desirazu N. Rao, et al.. (2012). Antibody-mediated catalysis: Induction and therapeutic relevance. Autoimmunity Reviews. 12(6). 648–652. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julie Pegon Breakdown of academic impact, for papers by Matthew W. Anderson Breakdown of academic impact, for papers by Y Hamano Breakdown of academic impact, for papers by Anne Schoolmeester Breakdown of academic impact, for papers by Kristell Lebozec Breakdown of academic impact, for papers by PI Terasaki Breakdown of academic impact, for papers by Cornelis E. Hack Breakdown of academic impact, for papers by Louis Deforche Breakdown of academic impact, for papers by Ria C. Boertjes Breakdown of academic impact, for papers by Karen Hambardzumyan
Rankless by CCL
2026